Lutetium-177 (Lu-177) Market Share, Sales Volume, Price Analysis Report 2026

Lutetium-177 (Lu-177) is a radioactive isotope of lutetium, a rare-earth metal with the atomic number 71. It has a half-life of approximately 6.6 days and emits beta and gamma radiation. Lutetium-177 is used in nuclear medicine for the treatment of various cancers, such as neuroendocrine tumors, breast cancer, and prostate cancer. It is often combined with other radionuclides or chelating agents to form radiolabeled tracers for imaging or therapeutic purposes.
Targeted cancer therapy: Lu-177 can be used to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. It achieves targeted therapy of tumors by binding to somatostatin receptors on the tumor surface.
Prostate cancer treatment: Lu-177 can combine with prostate-specific membrane antigen (PSMA) to form Lu-177 PSMA, which is used to treat advanced prostate cancer. This treatment shrinks or kills tumor cells and relieves pain and other clinical manifestations of metastatic prostate cancer.
Neuroendocrine tumor treatment: Neuroendocrine tumors express somatostatin receptors, so Lu-177 can bind to these receptors to achieve targeted therapy of tumors. Compared with traditional cancer treatments, Lu-177 treatment reduces hospital stay, does not affect healthy tissue, and is safe and well-tolerated.

According to our (Global Info Research) latest study, the global Lutetium-177 (Lu-177) market size was valued at US$ 2169 million in 2024 and is forecast to a readjusted size of USD 6241 million by 2031 with a CAGR of 16.5% during review period.

Market Drivers:
1. The growing global incidence of cancer, particularly neuroendocrine tumors (NETs) and prostate cancer, is a primary driver for Lu-177. As a targeted radionuclide, it offers a potent therapeutic option for patients with advanced or metastatic disease, creating sustained clinical demand and supporting market expansion.
2. Significant advancements in radiopharmaceutical theranostics are propelling Lu-177 adoption. The pairing of Lu-177 (therapy) with imaging agents like Ga-68 DOTATATE enables precise patient selection, treatment planning, and response monitoring, improving therapeutic outcomes and driving clinical acceptance.
3. Increasing regulatory approvals and positive clinical trial data for Lu-177-based therapies, such as Lutathera for NETs and Pluvicto for prostate cancer, validate its efficacy and safety. These approvals facilitate reimbursement pathways and encourage broader adoption within mainstream oncology practice.

Development Opportunities:
1. There is substantial opportunity for expanding the clinical application of Lu-177 into new cancer indications beyond current uses. Ongoing research explores its potential in breast cancer, glioblastoma, and other malignancies, which could significantly widen the patient population and market scope.
2. The development of novel Lu-177-labeled ligands and combination therapies presents a key opportunity. Innovating new targeting molecules (e.g., against different antigens) and combining Lu-177 with other therapeutic modalities like immunotherapy or chemotherapy could enhance efficacy and address resistance mechanisms.
3. Global expansion of production and distribution networks offers a major growth opportunity. Establishing more regional manufacturing and supply chains, especially in emerging markets with rising healthcare investment, can improve treatment accessibility and meet unmet medical needs worldwide.

Market Restraints:
1. The complex and costly supply chain for Lu-177 poses a significant challenge. Its production requires specialized nuclear reactors or accelerators, and the isotope's short half-life (6.65 days) necessitates rapid, logistically intricate transportation and preparation, limiting widespread availability.
2. High treatment costs and variable reimbursement policies hinder market penetration. The expense of radiopharmaceuticals, accompanying diagnostic scans, and multidisciplinary care can be substantial, and inconsistent insurance coverage across regions creates barriers to patient access.
3. A shortage of specialized healthcare infrastructure and trained personnel restrains market growth. Effective Lu-177 therapy requires specialized nuclear medicine departments, cyclotron or reactor access, and multidisciplinary teams of nuclear physicians, oncologists, and radiopharmacists, which are not universally available.

Chapter 1, to describe Lutetium-177 (Lu-177) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Lutetium-177 (Lu-177), with price, sales quantity, revenue, and global market share of Lutetium-177 (Lu-177) from 2021 to 2025.
Chapter 3, the Lutetium-177 (Lu-177) competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Lutetium-177 (Lu-177) breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2025.and Lutetium-177 (Lu-177) market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Lutetium-177 (Lu-177).
Chapter 14 and 15, to describe Lutetium-177 (Lu-177) sales channel, distributors, customers, research findings and conclusion.

About Us:
Global Info Research
Web: https://www.globalinforesearch.com
CN: 0086-176 6505 2062
HK: 00852-58030175
US: 001-347 966 1888
Email: report@globalinforesearch.com

For more information, please refer to "Global Lutetium-177 (Lu-177) Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032". This report analyzes the supply and demand situation, development status, and changes in the industry, focusing on the development status of the industry, how to face the development challenges of the industry, industry development suggestions, industry competitiveness, and industry investment analysis and trend forecasts. The report also summarizes the overall development dynamics of the industry, including the impact of the latest US tariffs on the global supply chain, the supply relationship analysis of the industrial chain, and provides reference suggestions and specific solutions for the industry in terms of products.

This release was published on openPR.